Who are the top shareholders of the Vimta Labs?

The top shareholders of Vimta Labs include Eurofins Analytical Services India Pvt Ltd with 19.81%, individual investors with 25.17%, and promoter Sivalinga Prasad Vasireddi holding 11.69%. Additionally, 30 foreign institutional investors hold a combined 3.66%, while mutual funds have a negligible stake of 0.0%.

The top shareholders of Vimta Labs include several key players. The largest public shareholder is Eurofins Analytical Services India Pvt Ltd, holding 19.81%. Among individual investors, they collectively own 25.17%. On the promoter side, Sivalinga Prasad Vasireddi has the highest individual holding at 11.69%. Additionally, the company has 30 foreign institutional investors (FIIs) with a combined holding of 3.66%. There are also two mutual fund schemes that hold shares, but their combined stake is negligible at 0.0%.

What does Vimta Labs do?

Vimta Labs Ltd. is a leading contract research and testing organization in India, established in 1984, with a market cap of Rs 2,103 Cr and reported net sales of 94 Cr and net profit of 18 Cr for March 2025. Key metrics include a P/E of 35.00 and a return on equity of 17.82%.

Overview:<BR>Vimta Labs Ltd. is India's most comprehensive contract research and testing organization, operating in the Healthcare Services industry within the Small Cap market-cap bracket.<BR><BR>History:<BR>Vimta Labs Ltd. was established in 1984. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 94 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 18 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 2,103 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 17.82% <BR>Price to Book: 6.24 <BR><BR>Contact Details:<BR>Address: Plot No 141/2 & 142, IDA Phase II Cherlapally Hyderabad Telangana : 500051 <BR>Tel: 91-40-27264141 <BR>Email: shares@vimta.com <BR>Website: http://www.vimta.com

Has Vimta Labs declared dividend?

Yes, Vimta Labs Ltd has declared a 100% dividend, amounting to ₹2 per share, with an ex-date of May 30, 2025. The company has shown strong total returns over various periods, particularly in price appreciation.

Vimta Labs Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 2 per share<BR>- Ex-date: May 30, 2025<BR><BR>Dividend Yield: 0.42%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was 1.55%, the dividend return was 0.22%, resulting in a total return of 1.77%.<BR><BR>In the 1-year period, the price return was 96.22%, with a dividend return of 0.81%, leading to a total return of 97.03%.<BR><BR>For the 2-year period, the price return was 131.01%, the dividend return was 1.47%, culminating in a total return of 132.48%.<BR><BR>During the 3-year period, the price return stood at 182.98%, the dividend return was 1.88%, which resulted in a total return of 184.86%.<BR><BR>In the 4-year period, the price return was 289.22%, with a dividend return of 3.19%, achieving a total return of 292.41%.<BR><BR>Over the 5-year period, the price return reached 1062.16%, the dividend return was 11.74%, resulting in a total return of 1073.9%.<BR><BR>Overall, Vimta Labs has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in price appreciation, suggesting a positive outlook for investors.

Who are the peers of the Vimta Labs?

Vimta Labs' peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Laxmi Dental, Krsnaa Diagnost., Tarsons Products, Suraksha Diagno., and 3B Blackbio. Vimta Labs has an average management risk, good growth rating, and the highest 1-year return among peers at 105.18%.

Peers: The peers of Vimta Labs are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Laxmi Dental, Krsnaa Diagnost., Tarsons Products, Suraksha Diagno., and 3B Blackbio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Tarsons Products, and Average management risk is noted at Vimta Labs, Krsnaa Diagnost., and Suraksha Diagno. Growth is rated as Excellent for 3B Blackbio, Good for Vimta Labs and Laxmi Dental, Average for Poly Medicure and Indegene, and Below Average for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Krsnaa Diagnost. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Krsnaa Diagnost., Good for Laxmi Dental and Suraksha Diagno., and Average for Vimta Labs and Tarsons Products.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vimta Labs at 105.18%, while the peer with the lowest is Tarsons Products at -6.12%. Vimta Labs' 1-year return significantly outperforms all peers. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

What is the bonus history of the Vimta Labs?

Vimta Labs recently announced a 1:1 bonus issue, with an ex-date of June 13, 2025. Shareholders on record as of this date will receive one additional share for each share they own.

Vimta Labs has a recent bonus issue where they announced a 1:1 bonus. The ex-date for this bonus is June 13, 2025, which means that shareholders on record as of this date will receive one additional share for every share they own. This is the latest information regarding their bonus history. If you have any more questions about Vimta Labs or need further details, feel free to ask!

Who are in the management team of Vimta Labs?

As of March 2023, the management team of Vimta Labs includes S P Vasireddi (Executive Chairman), Harita Vasireddi (Managing Director), and several non-executive directors, contributing to the company's governance and operations.

As of March 2023, the management team of Vimta Labs includes:<BR><BR>1. S P Vasireddi - Executive Chairman<BR>2. V Harriman - Director (Operation)<BR>3. Harita Vasireddi - Managing Director<BR>4. Y Prameela Rani - Non-Executive & Independent Director<BR>5. Sujani Vasireddi - Company Secretary & Compliance Officer<BR>6. G Purnachandra Rao - Non-Executive & Independent Director<BR>7. Sanjay Dave - Non-Executive & Independent Director<BR>8. Satya Sreenivas Neerukonda - Executive Director<BR>9. Yadagiri R Pendri - Non-Executive & Independent Director<BR><BR>This team comprises a mix of executive and non-executive members, contributing to the governance and operational management of the company.

How big is Vimta Labs?

As of 24th July, Vimta Labs Ltd has a market capitalization of 2,304.00 Cr, with recent Net Sales of 329.23 Cr and a Net Profit of 61.38 Cr. Shareholder's Funds are 319.70 Cr and Total Assets are valued at 392.25 Cr as of March 2024.

As of 24th July, Vimta Labs Ltd has a market capitalization of 2,304.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Vimta Labs reported Net Sales of 329.23 Cr and a Net Profit of 61.38 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 319.70 Cr and Total Assets valued at 392.25 Cr.

Is Vimta Labs overvalued or undervalued?

As of July 28, 2025, Vimta Labs is considered very expensive with a PE ratio of 47.77 and other high valuation metrics, indicating it is overvalued despite a favorable PEG ratio of 0.84 and strong past performance.

As of 28 July 2025, the valuation grade for Vimta Labs has moved from expensive to very expensive. Based on the analysis, the company appears to be overvalued. The PE ratio stands at 47.77, the Price to Book Value is 8.51, and the EV to EBITDA ratio is 25.60, all indicating a premium valuation relative to its peers.<BR><BR>In comparison to its industry peers, Vimta Labs' PE ratio is lower than that of Poly Medicure, which has a PE of 58.98, but higher than Blue Jet Health at 38.38. Notably, Vimta's PEG ratio of 0.84 suggests a more favorable growth expectation relative to its price, yet the overall high valuation metrics indicate that the stock is trading at a significant premium. Furthermore, Vimta Labs has outperformed the Sensex over various time frames, including a 137.30% return over the past year, which reinforces the perception of overvaluation given the current high price levels.

Is Vimta Labs technically bullish or bearish?

As of October 10, 2025, Vimta Labs shows a mildly bullish trend supported by bullish MACD and Bollinger Bands, but tempered by a mildly bearish Dow Theory signal and a lack of momentum confirmation from the RSI.

As of 10 October 2025, the technical trend for Vimta Labs has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and mildly bullish Bollinger Bands on the weekly chart. The daily moving averages also indicate a mildly bullish trend. However, the Dow Theory shows a mildly bearish signal on the weekly time frame, which tempers the overall bullish outlook. The RSI indicates no signal on both weekly and monthly time frames, suggesting a lack of momentum confirmation. Overall, the strength of the bullish stance is moderate, with some caution due to the mixed signals from Dow Theory and the RSI.

When is the next results date for Vimta Labs?

Vimta Labs will announce its results on 03 November 2025.

Vimta Labs will declare its results on 03 November 2025.

Are Vimta Labs latest results good or bad?

Vimta Labs' Q2 FY26 results are strong, with a 140.92% increase in net profit to ₹15.25 crore and a 29.30% revenue growth to ₹84.74 crore, alongside improved operating margins. However, the stock price fell by 5.94% post-announcement, indicating investor caution despite the positive financial performance.

Vimta Labs' latest results for Q2 FY26 are quite strong, showcasing significant growth and improved profitability. The company reported a net profit of ₹15.25 crore, which marks a remarkable 140.92% increase year-on-year. Additionally, revenue grew by 29.30% compared to the same quarter last year, reaching ₹84.74 crore. <BR><BR>The operating margin also saw substantial improvement, rising to 35.28%, up from 26.56% in the previous year, indicating enhanced operational efficiency. The return on equity (ROE) stands at a solid 17.82%, reflecting effective capital utilization.<BR><BR>Despite these positive results, the market reacted with a decline in the stock price, which fell by 5.94% following the announcement. This pullback may be attributed to profit-taking after a significant rally in the stock price over the past year. Overall, while the financial performance indicates strong fundamentals, the recent stock price movement suggests some caution among investors regarding valuation levels.

How has been the historical performance of Vimta Labs?

Vimta Labs' historical performance shows mixed results, with net sales decreasing to 288.60 Cr in March 2024 from 318.19 Cr in March 2023, while profit after tax increased to 48.81 Cr. Total assets rose to 392.25 Cr, but cash flow from operating activities fell to 60.00 Cr, resulting in a net cash outflow of 17.00 Cr.

Answer:<BR>The historical performance of Vimta Labs shows a mixed trend in its financial metrics over the past five years.<BR><BR>Breakdown:<BR>Vimta Labs reported net sales of 288.60 Cr in March 2024, a decrease from 318.19 Cr in March 2023, but an increase from 278.28 Cr in March 2022. The total operating income followed a similar pattern, with 288.60 Cr in March 2024 compared to 318.19 Cr in the previous year. The total expenditure, excluding depreciation, decreased to 194.56 Cr in March 2024 from 223.28 Cr in March 2023. Operating profit (PBDIT) slightly declined to 97.75 Cr in March 2024 from 98.35 Cr in March 2023, while profit before tax decreased to 62.50 Cr from 65.00 Cr in the same period. However, profit after tax increased to 48.81 Cr in March 2024 from 48.17 Cr in March 2023. The earnings per share (EPS) fell to 18.51 in March 2024 from 21.75 in March 2023, reflecting a decrease in profitability per share. On the balance sheet, total assets rose to 392.25 Cr in March 2024 from 358.01 Cr in March 2023, while total liabilities also increased to 392.25 Cr from 358.01 Cr. The cash flow from operating activities decreased to 60.00 Cr in March 2024 from 87.00 Cr in March 2023, contributing to a net cash outflow of 17.00 Cr in March 2024, compared to a net inflow of 19.00 Cr in March 2023.

Should I buy, sell or hold Vimta Labs?

Which are the latest news on Vimta Labs?

Why is Vimta Labs falling/rising?

As of 03-Dec, Vimta Labs Ltd's stock price is rising to 612.00, indicating a potential shift in market sentiment after a decline. The stock has shown strong long-term growth and outperformed its sector, with increased investor participation and a favorable debt-to-equity ratio.

As of 03-Dec, Vimta Labs Ltd's stock price is rising, currently at 612.00, reflecting an increase of 7.7 (1.27%). This upward movement follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. The stock has outperformed its sector by 1.51% today, suggesting that it is gaining traction among investors.<BR><BR>Additionally, there has been a notable increase in investor participation, with delivery volume rising by 1.5% against the 5-day average, which indicates growing interest in the stock. The company also maintains a low debt-to-equity ratio of 0.03 times, which is favorable for its financial health. Furthermore, Vimta Labs has demonstrated strong long-term growth, with operating profit increasing at an annual rate of 46.76% and positive results reported for the last four consecutive quarters.<BR><BR>Despite a decline of 10.28% over the past month, the stock has shown impressive performance year-to-date, with a return of 23.02%, significantly outperforming the market benchmark. This combination of factors contributes to the stock's current rise, reflecting both a recovery from recent lows and strong underlying financial performance.